The effects of riociguat, an oral-soluble guanylate-cyclase stimulator, were studied in 10 infants with chronic pulmonary arterial hypertension. Respiratory status (n = 8/10), right heart dilation (n = 7/10), function (n = 9/10), and chronic pulmonary arterial hypertension (n = 8/10) improved. Median decrement in systolic (12 [4, 14]), diastolic (14 [7, 20]), and mean arterial (14 [10, 17]) pressures were noted; no critical hypotension or hypoxemia occurred.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jpeds.2022.11.026 | DOI Listing |
Publication Analysis
Top Keywords
chronic pulmonary
12
pulmonary arterial
12
arterial hypertension
12
safety feasibility
4
feasibility riociguat
4
riociguat therapy
4
therapy treatment
4
treatment chronic
4
arterial
4
hypertension infancy
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!